Recombinant Human Thrombopoietin is made using genetic recombination technology, similar to endogenous thrombopoietin like substances, can stimulate the bone marrow to produce platelets. Recombinant human thrombopoietin is commonly used in clinics to treat thrombocytopenia, such as primary thrombocytopenia and thrombocytopenia after tumor chemotherapy. However, the use of the drug is generally not recommended for patients who are allergic to the drug, have severe cardiovascular and cerebrovascular diseases, hypercoagulable state of blood, and pregnant women. The use of the drug also requires monitoring of blood routine, should not be excessive elevation of platelets, adverse reactions include rash, diarrhea, thrombosis, worsening of malignant tumors and so on. In conclusion, the drug needs to be used under medical supervision, especially following the advice of a hematologist.